HealthDay on MSN7h
FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
The U.S. Food and Drug Administration approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Despite past performance issues, Arvinas has a solid cash runway. Learn more about ARVN stock's potential and why a cautious ...
News Medical on MSN4h
FDA-approved breast cancer drug shows promise for appendix cancer
Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of ...
Breast cancer drug shows potential for rare appendix cancer
Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer ...
Targeted Oncology12h
FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...
Targeted Oncology10h
KEYNOTE-522 Trial: Pembrolizumab Boosts Survival in Early TNBC
In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...